New biomonitoring methodologies to measure DNA adducts in human tissues
Project Number7R01ES019564-04
Contact PI/Project LeaderTURESKY, ROBERT J.
Awardee OrganizationUNIVERSITY OF MINNESOTA
Description
Abstract Text
DESCRIPTION (provided by applicant): The objective of this proposal is to develop new biomonitoring methodologies designed to measure DNA adducts in tissues of humans exposed to chemical carcinogens. Our chemical model for this project is structurally related nitro-phenanthrene carboxylic acids, a class of human carcinogens and nephrotoxicants that include aristolochic acids (AA). These compounds are universally present in herbs of the genus Aristolochia, used for medicinal purposes throughout the world for 2000 years. The nephrotoxicity and carcinogenicity of herbs containing AA are very well documented. Epidemiologic studies reveal AA to be the causal agent for the clinical syndromes known as Chinese herb and Balkan endemic nephropathies. In the latter, exposure to AA involves ingestion of bread prepared from flour contaminated with seeds of Aristolochia clematitis. Due to their toxicities, importation of traditional Chinese herbs containing AA are banned in some, but not all countries. Despite the Food and Drug Administration's warnings concerning the safety of botanical remedies containing AA, these herbs are still widely distributed in the United States via the Internet, and the incidence of chronic renal failure and urothelial cancer worldwide attributed to exposure to AA remains very high. Recently, we provided unequivocal evidence for the presence of AA-DNA adducts in the renal cortex of patients affected by BEN, using a novel, multi-stage ion trap mass spectrometry (MSn) method. Quantitative MS methods are essential for measuring DNA adduct biomarkers of this devastating and uniformally fatal disease. The biomonitoring methods will be used in translational research studies conducted in Balkan countries where the residents have dietary exposure to AA. A critical technological advance in DNA adduct screening methodologies will be achieved by extending the analysis of AA-DNA adducts from freshly frozen tissue samples to archived, formalin-fixed renal tissues, an untapped but rich source of material for toxico- logical research. Finally, a novel screening method will be established, employing an automated chip-based infusion nano-electrospray tandem MS method. This technique will provide a rapid throughput and cost- effective method to screen for DNA adducts in population-based studies. Traditional herbal remedies containing carcinogenic AA are used worldwide and are a global health problem. Recent epidemiological studies have linked herbs containing AA with renal failure and cancer. Rapid and quantitative analytical MS data to screen for AA-DNA adducts are needed to assess the exposure and the causal role of AA in nephropathy and upper urothelial cancer risk. The AA-DNA adducts also serve as critical biomarkers in studies of genetic susceptibility to Balkan endemic nephropathy and its associated upper urothelial cancer. The novel biomonitoring techniques established in this application can be appllied to examine the role of other chemical carcinogens in the etiology of human cancer.
Public Health Relevance Statement
Project Narrative: Novel mass spectrometry biomonitoring methods will be established to measure DNA
adducts of aristolochic acids (AA), potent nephrotoxicants and carcinogens found in herbs of the genus
Aristolochia, which have been used for medicinal purposes world-wide. These novel screening techniques will
be employed to measure AA-DNA adducts in human populations exposed to AA and diagnosed with upper
urothelial cancer.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AffectAnimalsArchivesAristolochiaAristolochic AcidsBalkan NephropathyBalkansBiologicalBiological AssayBiological MarkersBiological MonitoringBotanicalsBreadC3H/He MouseCancer PatientCarboxylic AcidsCarcinogensChemical ModelsChinese HerbsChromatographyChronic Kidney FailureClinicalCountryCroatiaDNADNA AdductionDNA AdductsDNA Repair EnzymesDataDiagnosisDietDiseaseEpidemiologic StudiesEtiologyExposure toFlourFormalinFreezingFundingGenesGenetic Predisposition to DiseaseGoalsHerbHumanIncidenceIndividualInfusion proceduresIngestionInternetIonsKidneyKidney DiseasesKidney FailureLaboratoriesLesionLinkMalignant NeoplasmsMass FragmentographyMass Spectrum AnalysisMeasurementMeasuresMethodologyMethodsModelingMolecularMolecular ToxicologyMusMutationNephrotoxicPO-1PatientsPopulation StudyPublic HealthRadioactivityRenal TissueRenal carcinomaResearchRetrievalRiskRoleRuralSafetySamplingSeedsSourceSpecimenStagingStructureStudy SubjectSyndromeTP53 geneTechniquesTimeTissue SampleTissuesToxic effectToxicogenomicsTranslational ResearchUnited StatesUnited States Food and Drug AdministrationUnited States National Institutes of HealthXenobiotic Metabolismadductbasecancer riskcarcinogenicitycase controlchemical carcinogencost effectivedesignexposed human populationglobal healthhuman tissuekidney cortexliquid chromatography mass spectrometrymass spectrometernano-electrospraynephrotoxicitynovelphenanthrenepopulation basedprogramsresearch studyrural areascreeningtissue fixingtoxicant
National Institute of Environmental Health Sciences
CFDA Code
113
DUNS Number
555917996
UEI
KABJZBBJ4B54
Project Start Date
01-February-2011
Project End Date
31-January-2015
Budget Start Date
19-September-2013
Budget End Date
31-January-2015
Project Funding Information for 2013
Total Funding
$339,680
Direct Costs
$234,798
Indirect Costs
$104,882
Year
Funding IC
FY Total Cost by IC
2013
National Institute of Environmental Health Sciences
$339,680
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R01ES019564-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01ES019564-04
Patents
No Patents information available for 7R01ES019564-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01ES019564-04
Clinical Studies
No Clinical Studies information available for 7R01ES019564-04
News and More
Related News Releases
No news release information available for 7R01ES019564-04
History
No Historical information available for 7R01ES019564-04
Similar Projects
No Similar Projects information available for 7R01ES019564-04